Skip to content
Search

Latest Stories

DHSC releases second list of January price concessions

The Department of Health and Socialcare (DHSC) today published its second list of price concessions for January 2020.

The announcement, revealed by the PSNC, follows the first announcement on January 15.


The latest list (below) covers 32 drugs.

Amiloride 5mg tablets28£22.38
Co-careldopa 25mg/100mg tablets100£10.69
Diclofenac sodium 75mg modified-release tablets56£15.00
Fluoxetine 10mg capsules30£47.50
Hydroxyzine 10mg tablets84£2.12
Hydroxyzine 25mg tablets28£1.09
Irbesartan 75mg tablets28£2.80
Irbesartan 300mg tablets28£5.53
Irbesartan 300mg / Hydrochlorothiazide 12.5mg tablets28£4.99
Lamotrigine 25mg dispersible tablets sugar free56£9.71
Levetiracetam 250mg tablets60£3.60
Lymecycline 408mg capsules28£5.70
Meloxicam 7.5mg tablets30£2.80
Meloxicam 15mg tablets30£5.60
Memantine 10mg tablets28£3.20
Memantine 20mg tablets28£8.05
Mirtazapine 15mg tablets28£2.10
Mirtazapine 30mg tablets28£2.20
Mirtazapine 45mg tablets28£2.40
Nefopam 30mg tablets90£14.96
Nitrazepam 5mg tablets28£2.70
Nitrofurantoin 50mg tablets28£13.27
Nitrofurantoin 100mg tablets28£9.32
Oxytetracycline 250mg tablets28£4.93
Ranitidine 300mg tablets30£4.80
Rivastigmine 3mg capsules28£4.29
Sulpiride 200mg tablets30£6.48
Tolterodine 2mg tablets56£2.62
Trihexyphenidyl 2mg tablets84£7.95
Venlafaxine 37.5mg tablets56£7.90
Venlafaxine 75mg tablets56£14.50

More For You

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less